Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects

November 5, 2023 updated by: Daewoong Pharmaceutical Co. LTD.

A Two-arm, Open-label, Single-sequence, Multiple Oral Dosings, Crossover Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of DWC202313 and DWC202314 in Healthy Adult Volunteers

This is A two-arm, open-label, single-sequence, multiple oral dosings, crossover study to evaluate the safety and the pharmacokinetic interaction of DWC202313 and DWC202314 in healthy adult volunteers.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

32

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Seung-Hyun Kang, MD, Ph D
  • Phone Number: 070-4665-9490
  • Email: juspa@newyjh.com

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • over 19 year old

Exclusion Criteria:

  • Galactose intolerance
  • Lapp lactase deficiency

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: DWC202313
Drug: DWC202313
Experimental Drug 1
Experimental: DWC202314
Drug: DWC202314
Experimental Drug 2

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Cmax,ss of DWC202313 and DWC202314
Time Frame: Up to 14 days
Up to 14 days
AUCt,ss of DWC202313 and DWC202314
Time Frame: Up to 14 days
Up to 14 days

Secondary Outcome Measures

Outcome Measure
Time Frame
Tmax,ss of DWC202313 and DWC202314
Time Frame: Up to 14 days
Up to 14 days
Cmin,ss of DWC202313 and DWC202314
Time Frame: Up to 14 days
Up to 14 days
t1/2 of DWC202313 and DWC202314
Time Frame: Up to 14 days
Up to 14 days
CLss/F of DWC202313 and DWC202314
Time Frame: Up to 14 days
Up to 14 days
Vdss/F of DWC202313 and DWC202314
Time Frame: Up to 14 days
Up to 14 days
PTF of DWC202313 and DWC202314
Time Frame: Up to 14 days
Up to 14 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Daewoong Pharmaceutical Co. LTD.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 27, 2023

Primary Completion (Estimated)

December 1, 2023

Study Completion (Estimated)

December 1, 2023

Study Registration Dates

First Submitted

October 23, 2023

First Submitted That Met QC Criteria

November 5, 2023

First Posted (Actual)

November 7, 2023

Study Record Updates

Last Update Posted (Actual)

November 7, 2023

Last Update Submitted That Met QC Criteria

November 5, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • DWJ1622101

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Drug Drug Interaction

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe